Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Karakasis, Paschalis; Fragakis, Nikolaos; Kouskouras, Konstantinos; Karamitsos, Theodoros; Patoulias, Dimitrios; Rizzo, Manfredi

doi:10.1016/j.clinthera.2024.06.010

Clinical Therapeutics

2024

DOI: 10.1016/j.clinthera.2024.06.010

|View full text |Cite

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Paschalis Karakasis,

Nikolaos Fragakis,

Konstantinos Kouskouras

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 9 publications

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies

Maron

2024

Clinical Therapeutics

View full text Add to dashboard Cite

Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies

Maron

2024

Clinical Therapeutics

View full text Add to dashboard Cite

Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update

Alam

2024

Clinical Therapeutics

View full text Add to dashboard Cite

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?

Karakasis,

Sagris,

Patoulias

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Obstructive sleep apnea (OSA) is a prevalent condition associated with increased cardiovascular risk, particularly in individuals with comorbid obesity and type 2 diabetes (T2D). Despite the widespread use of continuous positive airway pressure (CPAP) for OSA management, adherence remains suboptimal, and CPAP has not consistently demonstrated reductions in surrogate cardiovascular events. Recently, attention has focused on glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors as potential therapeutic agents for mitigating cardiovascular risk in OSA patients. These agents, originally developed for T2D management, have demonstrated pleiotropic effects, including significant weight loss, blood pressure reduction, and amelioration of endothelial dysfunction and arterial stiffness, along with anti-inflammatory benefits, which may be particularly beneficial in OSA. Emerging clinical evidence suggests that GLP-1RAs and SGLT2 inhibitors can reduce OSA severity and improve daytime sleepiness, potentially reversing the adverse cardiovascular effects observed in OSA. This review explores the pathophysiological mechanisms linking OSA with cardiovascular disease and evaluates the potential therapeutic roles of GLP-1RAs and SGLT2 inhibitors in addressing cardiovascular risk in OSA patients. Further research, including long-term clinical trials, is necessary to establish the effectiveness of these therapies in reducing cardiovascular events and improving patients’ reported outcomes in this population.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Acute Coronary Syndrome: A Modern Cinderella?

Cited by 9 publications

References 97 publications

Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies

Silver Linings: Side Effects and Secondary Findings of Newly Emerging Therapies

Extraglycemic Effects of SGLT2i/GLP1-ra: A Topic Update

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?

Contact Info

Product

Resources

About